Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

2021 News

Archives

Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA

Endologix Names Dr. Matthew Thompson President and CEO

Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System

Endologix LLC Receives FDA Breakthrough Device Designation for ChEVASTM System

Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina Company Expands Global Reach with Latest Endovascular Aneurysm Repair (EVAR) Technology